Surgical upstaging rates in patients meeting the eligibility for active surveillance trials

CONCLUSIONS: The upstaging rate in patients eligible for the clinical active surveillance trials was 12-25%. Although the rate of upstaging to pT1b or higher was low, further studies are required to determine the rates of upstaging to invasive cancer and the risk factors among patients with low-risk ductal carcinoma in situ.PMID:34091677 | DOI:10.1093/jjco/hyab082

Source: Clinical Genitourinary Cancer - June 6, 2021 Category: Cancer & Oncology Authors: Naoko Iwamoto Miyako Nara Shin-Ichiro Horiguchi Tomoyuki Aruga Source Type: research